Felidale

Main information

  • Trade name:
  • Felidale 1.25 mg Coated Tablets for Cats
  • Pharmaceutical form:
  • Coated tablet
  • Prescription type:
  • POM-V - Prescription Only Medicine – Veterinarian
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Felidale 1.25 mg Coated Tablets for Cats
    United Kingdom
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Cats
  • Therapeutic area:
  • Anti Hormone Agent

Status

  • Source:
  • VMD - Veterinary Medicines Directorate
  • Authorization status:
  • Authorized
  • Authorization number:
  • 10434/4092
  • Authorization date:
  • 06-12-2017
  • Last update:
  • 19-01-2018

Summary of Product characteristics: dosage, interactions, side effects

Revised: May 2019

AN: 01557/2018

SUMMARY OF PRODUCT CHARACTERISTICS

1.

NAME OF THE VETERINARY MEDICINAL PRODUCT

Felidale 1.25 mg coated tablets for cats

2.

QUALITATIVE AND QUANTITATIVE COMPOSITION

1 tablet contains:

Active substance:

Thiamazole

1.25 mg

Excipients:

Titanium Dioxide (E171)

0.51 mg

Dispersed Ponceau 4R Lake (E124)

1.35 mg

For the full list of excipients, see section 6.1.

3.

PHARMACEUTICAL FORM

Coated tablet.

Red sugar-coated biconvex tablets 5.5 mm diameter.

4.

CLINICAL PARTICULARS

4.1

Target species

Cats.

4.2

Indications for use, specifying the target species

For the stabilisation of hyperthyroidism in cats prior to surgical thyroidectomy.

For the long-term treatment of feline hyperthyroidism.

4.3

Contraindications

Do not use in cats suffering from systemic disease such as primary liver disease or

diabetes mellitus.

Do not use in cats showing signs of autoimmune disease.

Do not use in animals with disorders of white blood cells, such as neutropenia and

lymphopenia.

Do not use in animals with platelet disorders and coagulopathies (particularly

thrombocytopenia).

Do not use in cats with hypersensitivity to thiamazole or the excipient, polyethylene

glycol.

Do not use in pregnant or lactating females.

Please refer to section 4.7.

Page 1 of 6

Revised: May 2019

AN: 01557/2018

4.4

Special warnings

As thiamazole can cause haemoconcentration, cats should always have access to

drinking water.

4.5

Special precautions for use

Special precautions for use in animals

If more than 10 mg per day is required animals should be monitored particularly

carefully.

Use of the product in cats with renal dysfunction should be subject to careful risk :

benefit assessment by the clinician. Due to the effect thiamazole can have on

reducing the glomerular filtration rate, the effect of therapy on renal function should

be monitored closely as deterioration of an underlying condition may occur.

Haematology must be monitored due to risk of leucopenia or haemolytic anaemia.

Any animal that suddenly appears unwell during therapy, particularly if they are

febrile, should have a blood sample taken for routine haematology and biochemistry.

Neutropenic animals (neutrophil counts <2.5 x 10

/l) should be treated with

prophylactic bactericidal antibacterial drugs and supportive therapy.

Please refer to section 4.9 for monitoring instructions.

Special precautions to be taken by the person administering the veterinary medicinal

product to animals

Wash hands after use.

In the case of accidental ingestion, seek medical advice immediately and show the

package insert or the label to the physician.

Thiamazole may cause vomiting, epigastric distress, headache, fever, arthralgia,

pruritus and pancytopenia. Treatment is symptomatic.

Wash hands with soap and water after handling litter used by treated animals.

Do not eat, drink or smoke while handling the tablet or used litter.

Do not handle this product if you are allergic to antithyroid products. If allergic

symptoms develop, such as a skin rash, swelling of the face, lips or eyes or difficulty

in breathing, you should seek medical attention immediately and show the package

leaflet or label to the doctor.

Do not break or crush tablets.

As thiamazole is a suspected human teratogen, women of child-bearing age and

pregnant women should wear gloves when handling litter of treated cats.

Pregnant women should wear gloves when handling the product.

4.6

Adverse reactions (frequency and seriousness)

Adverse reactions have been reported following long term control of hyperthyroidism.

In many cases, signs may be mild and transitory and not a reason for withdrawal of

treatment. The more serious effects are mainly reversible when medication is

stopped.

Adverse reactions are uncommon. The most common clinical side effects that are

reported include vomiting, inappetance/anorexia, lethargy, severe pruritus and

excoriations of the head and neck, bleeding diathesis and icterus associated with

hepatopathy, and haematological abnormalities (eosinophilia, lymphocytosis,

neutropenia, lymphopenia, slight leucopenia, agranulocytosis, thrombocytopenia or

haemolytic anaemia). These side effects resolve within 7-45 days after cessation of

Page 2 of 6

Revised: May 2019

AN: 01557/2018

thiamazole therapy.

Possible immunological side effects include anaemia, with rare side effects including

thrombocytopenia and serum anti-nuclear antibodies, and, very rarely,

lymphadenopathy can occur. Treatment should be stopped immediately and

alternative therapy considered following a suitable period for recovery.

Following long-term treatment with thiamazole in rodents, an increased risk of

neoplasia in the thyroid gland has been shown to occur, but no evidence is available

in cats.

4.7

Use during pregnancy, lactation or lay

Laboratory studies in rats and mice have shown evidence of teratogenic and

embryotoxic effects of thiamazole. The safety of the product was not assessed in

pregnant or lactating cats. Do not use in pregnant or lactating females.

4.8

Interaction with other medicinal products and other forms of interaction

Concurrent treatment with phenobarbital may reduce the clinical efficacy of

thiamazole.

Thiamazole is known to reduce the hepatic oxidation of benzimidazole wormers and

may lead to increases in their plasma concentrations when given concurrently.

Thiamazole is immunomodulatory, therefore this should be taken into account when

considering vaccination programmes.

4.9

Amounts to be administered and administration route

For oral administration only.

For the stabilisation of feline hyperthyroidism prior to surgical thyroidectomy and for

the long term treatment of feline hyperthyroidism, the recommended starting dose is

5 mg per day.

Standard dose adjustments should be made in increments of 2.5 mg and the aim

should be to achieve the lowest possible dose rate.

Wherever possible, the total daily dose should be divided into two and administered

morning and evening. Tablets should not be split.

If, for reasons of compliance, once daily dosing with a 5 mg tablet is preferable, then

this is acceptable although the 2.5 mg tablet given twice daily may be more

efficacious in the short term. The 5 mg tablet is also suitable for cats requiring higher

dose rates.

1.25 mg tablets are intended for use in cats that require particularly small doses of

thiamazole, and to assist with dosage adjustments.

Haematology, biochemistry and serum total T4 should be assessed before initiating

treatment and after 3 weeks, 6 weeks, 10 weeks, 20 weeks, and thereafter every

3 months. At each of the recommended monitoring intervals, the dose should be

titrated to effect according to the total T4 and to clinical response to treatment. Dose

adjustments should be made in increments of 2.5 mg and the aim should be to

achieve the lowest possible dose rate.

If more than 10 mg per day is required animals should be monitored particularly

carefully.

The dose administered should not exceed 20 mg/day.

For long term treatment of hyperthyroidism, the animal should be treated for life.

Page 3 of 6

Revised: May 2019

AN: 01557/2018

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

In tolerance studies in young healthy cats, the following dose-related clinical signs

occurred at doses of up to 30 mg/animal/day: anorexia, vomiting, lethargy, pruritus

and haematological and biochemical abnormalities such as neutropenia,

lymphopenia, reduced serum potassium and phosphorus levels, increased

magnesium and creatinine levels and the occurrence of anti-nuclear antibodies. At a

dose of 30 mg/day some cats showed signs of haemolytic anaemia and severe

clinical deterioration. Some of these signs may also occur in hyperthyroid cats treated

at doses of up to 20 mg per day.

Excessive doses in hyperthyroid cats may result in signs of hypothyroidism. This is

however unlikely, as hypothyroidism is usually corrected by negative feedback

mechanisms. Please refer to Section 4.6: Adverse reactions.

If overdosage occurs, stop treatment and give symptomatic and supportive care.

4.11 Withdrawal period(s)

Not applicable.

5.

PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: antithyroid preparations: sulphur-containing imidazole

derivatives.

ATC Vet Code: QH03BB02.

5.1

Pharmacodynamic properties

Thiamazole acts by blocking the biosynthesis of thyroid hormone in vivo. The primary

action is to inhibit binding of iodide to the enzyme thyroid peroxidase, thereby

preventing the catalysed iodination of thyroglobulin and T

and T

synthesis.

5.2

Pharmacokinetic particulars

Following oral dosing in healthy cats, thiamazole is rapidly and completely absorbed

with a bioavailability of >75%. However, there is a considerable variation between

animals. Elimination of the drug from cat plasma is rapid with a half life of 4.5-

5.0 hours. Peak plasma levels occur approximately 1-2 hours after dosing. C

between 1.6-1.9 μg/ml.

In rats thiamazole has been shown to be poorly bound to plasma protein (5%); 40%

was bound to red blood cells. The metabolism of thiamazole in cats has not been

investigated, however, in rats thiamazole is rapidly metabolised in the thyroid gland.

About 64% of the administered dose being eliminated in the urine and only 7.8%

excreted in faeces. This is in contrast with man where the liver is important for the

metabolic degradation of the compound. The drug residence time in the thyroid

gland is assumed to be longer than in the plasma.

From man and rats it is known that the drug can cross the placenta and

concentrates in the foetal thyroid gland. There is also a high rate of transfer into

breast milk.

Page 4 of 6

Revised: May 2019

AN: 01557/2018

6.

PHARMACEUTICAL PARTICULARS

6.1

List of excipients

Tablet core:

Lactose monohydrate

Povidone

Sodium starch glycolate

Magnesium stearate

Coating:

Sucrose

Povidone

Dispersed Ponceau 4R Lake (E124)

Macrogol

Talc

White beeswax

Carnauba wax

Shellac

Titanium dioxide (E171)

Sodium methyl hydroxybenzoate (E219)

6.2

Major Incompatibilities

None known.

6.3

Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

6.4

Special precautions for storage

Do not store above 25

Tablet container: Keep the container tightly closed in order to protect from moisture.

Keep the container in the outer carton.

Blister: Keep the blister strips in the carton.

6.5

Nature and composition of immediate packaging

Tablet container: White polypropylene tub with white low density polyethylene tamper

evident lid containing 100 tablets.

Blister: Transparent PVC/Aclar – aluminium blister. Blister strips contain 25 tablets.

Each carton contains 4 blister strips.

6.6

Special precautions for the disposal of unused veterinary medicinal

product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste material derived from such veterinary

medicinal products should be disposed of in accordance with local requirements.

Page 5 of 6

Revised: May 2019

AN: 01557/2018

7.

MARKETING AUTHORISATION HOLDER

Dechra Limited

Snaygill Industrial Estate

Keighley Road

Skipton

North Yorkshire

BD23 2RW

8.

MARKETING AUTHORISATION NUMBER

Vm 10434/4092

9.

DATE OF FIRST AUTHORISATION

06 December 2017

10.

DATE OF REVISION OF THE TEXT

May 2019

Approved: 23 May 2019

Page 6 of 6